Navigation Links
Tengion Announces Second Closing of Series C Financing
Date:11/19/2008

Funds to Support Clinical Trials for Tengion Neo-Bladder(TM) Franchise

EAST NORRITON, Pa., Nov. 19 /PRNewswire/ -- Tengion Inc., a clinical stage regenerative medicine company focused on the development of neo-organs and neo-tissues, today announced that it has completed a second closing of its Series C financing, receiving a total of approximately $21 million in additional equity capital from the company's existing institutional equity investor base along with new investor, Safeguard Scientifics, Inc. Tengion also announced today that Gary J. Kurtzman, M.D., Vice President and Managing Director of Safeguard Scientifics' Life Sciences Group, has joined Tengion's Board of Directors.

In conjunction with the receipt of additional equity capital, Tengion successfully restructured a portion of its venture debt, which will positively contribute to its cash utilization in 2009.

Participants in this financing round include new investor Safeguard Scientifics, along with Tengion's full roster of current institutional investors: Bain Capital LLC, Johnson & Johnson Development Corporation, Deerfield Partners, Quaker BioVentures, Oak Investment Partners, HealthCap and L Capital Partners

"During this challenging time across the debt and equity markets, we feel that our ability to attract additional financing from leading biotech investors - both new and existing - exemplifies the strength of our data, the exp
'/>"/>

SOURCE Tengion Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
2. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
3. Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
4. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
5. Tengion Appoints Jeff Randall to Board of Directors
6. Tengion to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
8. Penguin Computing Announces Niveus HTX Personal Supercomputer
9. Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference
10. BBM Announces Offer to Acquire YM BioSciences Inc.
11. Covanta Announces Amended Terms for its Acquisition of Two Biomass Energy Facilities in Maine

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...c. 2 /PRNewswire-Asia-FirstCall/ -- Emerald Dairy,...etin Board: EMDY), a leading,producer and distribu...and,soybean products in China, today announced tha... of US Food & Drink Executive, a quarterly mag... in the food and beverage industry. , The...
(Date:12/2/2009)... According to the National Institu...s diagnosed with diabetes already have some stage ...mage to the retina caused by leaky blood vessels, ...tes and is one of the most feared diabetic complic... who,ve had diabetes for 10 years or more will exp...
(Date:12/1/2009)... Reportlinker.com announces that a...talogue: ,, Emerging Clinical Trial Locations ... healthcare and regulatory environment ,, htt...l-Trial-Locations---Eastern-Europe-Market-dynamics...nment.html ,, Over the last decade pharmaceuti...
(Date:12/1/2009)... 1 Expanding its European reach fo...arasota has appointed Lake Chemicals and Minerals ...d near Birmingham, England. ,, Osprey breeds t...ricultural, waste water, and environmental markets...rain fields, and clean up industrial and marine sp...
Breaking Biology Technology:Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8
...allows new scientific and business development fle.... 15 /PRNewswire-FirstCall/ - Resverlogix Corp.,("...s redeemed USD$10,million or approximately 60% of ... McCaffrey, President and CEO of Resverlogix state... and challenging for companies,around the globe. T...
...all and webcast to begin after markets close at 2:...ET), IRVINE, Calif., Oct. 15 Masimo Corporation,...y and,Measure-Through-Motion- and-Low-Perfusion pu...d quarter financial results for the period ended,S...y, October 27, 2008., A conference call to review...
..., Oct. 15 Strategic Healthcare,Group LLC announce...ith the,American Red Cross to provide Strategic Bl...00 American Red Cross client hospitals across the ...ghly successful Strategic Blood,Management(TM) pro...Birmingham Hospital and Baptist Hospital in Pensac...
Other Biology Technology:Resverlogix Eliminates Sixty Percent of Remaining Debt 2Masimo to Report Third Quarter 2008 Financial Results on October 27, 2008 2American Red Cross Expands Agreement for Strategic Blood Management(TM) Services from Strategic Healthcare Group LLC 2
(Date:11/30/2009)...orsyth Institute, the University of Connecticut He...e used state-of-the-art technology to elucidate th...e bacterium which causes syphilis. The previously ... be shown in three dimensions. This provides the f...usly unknown features, which may help fight the sp...
(Date:11/30/2009)...German . , The DFG has approved the establis...of 1 January 2010. This decision was made recently... centres will initially be funded for four years w...t overhead funding for indirect costs will also be...topics range from modern prostheses to political r...
(Date:11/30/2009)...ists and engineers from two of the nation,s larges...her Dec. 7 with leading academicians to explore th...uch like moving oil through a pipeline, the heart ...ed clean, well-functioning pipes (or blood vessels...iciently. Both industries also are crucial to our ...
Breaking Biology News(10 mins):Scientists gain new understanding of disease-causing bacteria 2DFG approves funding for 17 new collaborative research centers 2DFG approves funding for 17 new collaborative research centers 3DFG approves funding for 17 new collaborative research centers 4DFG approves funding for 17 new collaborative research centers 5DFG approves funding for 17 new collaborative research centers 6DFG approves funding for 17 new collaborative research centers 7DFG approves funding for 17 new collaborative research centers 8DFG approves funding for 17 new collaborative research centers 9Similarities of pumping blood and oil examined 2Similarities of pumping blood and oil examined 3Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcanos VH 28R 29 IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks 58307 1Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcanos VH 28R 29 IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks 58307 2Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcanos VH 28R 29 IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks 58307 3Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcanos VH 28R 29 IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks 58307 4Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcanos VH 28R 29 IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks 58307 5Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcanos VH 28R 29 IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks 58307 6Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcanos VH 28R 29 IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks 58307 7Results from Abbotts PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease 5062 1Results from Abbotts PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease 5062 2Results from Abbotts PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease 5062 3Results from Abbotts PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease 5062 4Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 1Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 2Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 3Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 4Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 5Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 6Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 7Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 8Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 9Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 10Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 11Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 12Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 13Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 14Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 15Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 16Reportlinker Adds Whos Doing What in Molecular Diagnostics 3F Kalorama Emmes Survey of US Laboratories Report 58303 17
... by invitation to an international scientific meet..., to identify strategies for the control of the on...ocusts stripped fields of crops and trees of folia... and food supply loss. , Larry Vaughan, associate...est Management Collaborative Research Support Prog...
...urther evidence that environmental factors could b...ies, published online today (Thursday 28 April) in...man Reproduction, suggest that environmental pollu...g the X or Y (sex determining) chromosomes and tha...tive disorders. , A study by Swedish researchers[1...
...accurate imaging technique have shed light on the ...terial within living cells. The motors cooperate i...gaging in the brute-force tug of war many scientis...lar motors -- dynein and kinesin -- do not compete...me cargo in opposite directions," said Paul Selvin...
Other Biology News:Scientists discuss improved biopesticides for locust control in West Africa 2How the environment could be damaging men's reproductive health 2How the environment could be damaging men's reproductive health 3How the environment could be damaging men's reproductive health 4Molecular Motors Cooperate In Moving Cellular Cargo, Study Shows 2
Rat Anti-Gamma delta T Lymphocytes Monoclonal Antibody, Unconjugated, Clone MAC320 from BD Biosciences Pharmingen
TE Buffer from Upstate
TE Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade from Research Organics, Inc.
Xylene Resistant (X/R) Red System, 1000 Tests (SIGNET) from Covance Research Products, Inc
Biology Products: